# Cycle Control and Safety of E2-DRSP

> **NCT00653614** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 635 (actual)

## Conditions studied

- Contraceptive, Oral, Hormonal

## Interventions

- **DRUG:** E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)
- **DRUG:** E2/DRSP (BAY 86-4891) dose 2 (80458739)
- **DRUG:** E2/DRSP (BAY 86-4891) dose 3 (80458755)
- **DRUG:** E2/DRSP (BAY 86-4891) dose 4 (80458720)
- **DRUG:** E2/DRSP (BAY 86-4891) dose 5 (80458712)
- **DRUG:** DRSP (ZK 30595) dose 1 (SH T04984F)
- **DRUG:** DRSP (ZK 30595) dose 2 (80458690)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00653614
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 635 (ACTUAL)
- **Last updated:** 2015-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00653614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00653614, "Cycle Control and Safety of E2-DRSP". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00653614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*